

25 June 2025


info@psgr.org.nz

Dear 

LOCAL GOVERNMENT OFFICIAL INFORMATION AND MEETINGS ACT Request: 2025-8

Thank you for your email and letter of 16 June 2025 to the Carterton District Council's Elected Members, attached as **Appendix One**.

Your request has been considered under the Local Government Official Information and Meeting Act 1987 (the Act).

You have sought a Local Government Official Information Act 1987 (LGOIMA) request for Councillors opinions on the Gene Technological Bill.

The purpose of the LGOIMA Act includes, amongst other things:

- a. *To increase progressively the availability to the public of **official information held by local authorities**.*

Carterton District Council has not had any discussion or papers presented relating to the Gene Technological Bill in any of our council meetings. Consequently, I am refusing your request under section 17(g) of the Act on the grounds Council holds no information on this subject.

Should you wish to obtain Councillors opinions on the Gene Technology Bill, these can be sought by contacting them individually. Councillors contact information is shown on our website here <https://cdc.govt.nz/your-council/electedreps/>.

Thank you again for your email and letter. You have the right to ask an Ombudsman to review this decision. You can do this by writing to info@ombudsman.parliament.nz or Office of the Ombudsman, PO Box 10152, Wellington 6143.

Yours sincerely



Geoff Hamilton
Chief Executive
Carterton District Council

28 Holloway Street, Carterton, Wairarapa | PO Box 9, Carterton, 5743
info@cdc.govt.nz | 06 379 4030 | www.cdc.govt.nz

LGOIMA ID: 2025-28

From: Mayor - Ron Mark
Sent: Thursday, 19 June 2025 9:56 am
To: LGOIMA Requests
Subject: FW: Letter to Councillors and LGOIMA request - Gene Technology Bill
Attachments: 2025-06-16 TLAs Do the GE regulatory promises on safety hold up under scrutiny.pdf

Follow Up Flag: Follow up
Flag Status: Completed

Hi LGOIMA,

On behalf of Ron, please treat the email below from the requestor as a LGOIMA.

Thanking you in advance.



[REDACTED] | Democratic Services Officer | Executive Assistant to Mayor

CARTERTON DISTRICT COUNCIL

Email: [REDACTED]@cdc.govt.nz

PO Box 9 Carterton 5743 | 28 Holloway Street Carterton 5713 | Website: www.cdc.govt.nz

From: Mayor - Ron Mark <Mayor@cdc.govt.nz>
Sent: Thursday, 19 June 2025 9:55 am
To: Geoff Hamilton <geoffh@cdc.govt.nz>
Cc: Grace Ayling <gracea@cdc.govt.nz>; Robyn Cherry-Campbell <robyn@cdc.govt.nz>; Steve Cretney <steve@cdc.govt.nz>; Brian Deller <briand@cdc.govt.nz>; Steve Gallon <steveg@cdc.govt.nz>; Steve Laurence <stevl@cdc.govt.nz>; Lou Newman <lou@cdc.govt.nz>; Mayor - Ron Mark <Mayor@cdc.govt.nz>; Geri Brooking <geri@cdc.govt.nz>
Subject: FW: Letter to Councillors and LGOIMA request - Gene Technology Bill

Morena Geoff

On behalf of Ron, email from Jodie Bruning received on Monday 16 June 2025. She would like her email to be treated as a LOGIMA.

I will proceed with registering [REDACTED] request as a LOGIMA and will send an acknowledgement email out today.

Please note the 20 working days response due date is by Tuesday 15 July 2025. The response date shown takes into account Matariki 20 June 2025.

Kind regards



CARTERTON DISTRICT COUNCIL

Email: ██████████@cdc.govt.nz

PO Box 9 Carterton 5743 | 28 Holloway Street Carterton 5713 | Website: www.cdc.govt.nz

From: ██████████ <info@psgr.org.nz>

Sent: Monday, 16 June 2025 6:03 pm

To: Mayor - Ron Mark <Mayor@cdc.govt.nz>; Dale Williams <dale@cdc.govt.nz>; Grace Ayling <grace@cdc.govt.nz>; Robyn Cherry-Campbell <robyn@cdc.govt.nz>; Steve Cretney <steve@cdc.govt.nz>; Brian Deller <briand@cdc.govt.nz>; Steve Gallon <steveg@cdc.govt.nz>; Steve Laurence <stevel@cdc.govt.nz>; Lou Newman <lou@cdc.govt.nz>

Subject: Letter to Councillors and LGOIMA request - Gene Technology Bill

Caution: This email originated from outside the council. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Councillors,

By now, elected members and staff at territorial and local authorities will be reading articles in local agricultural papers and in the accredited media, discussing the benefits to New Zealand of the [Gene Technology Bill](#), currently at the select committee stage. Public submissions closed in February, yet the report to the Select Committee remains unpublished.

We urge elected members to be circumspect. Few articles have frankly addressed the deficiencies in the policy formulation. This was highlighted by both scientists and legal experts in their Select Committee submissions. As elected members you recognise the importance of step-by-step processes that follow transparent and accountable stages, as per the Good Regulatory Practice guidelines. End-stage policy and law must be of high quality.

The Ministry for Business, Innovation and Employment and the Minister in charge, the Hon Judith Collins, advised all that they were pushing the policy and Bill through at a fast pace. Unfortunately, it shows. Neither a scientific case nor an economic case was made for the reforms. The evidence base in the Regulatory Impact Statement does not demonstrate that gene edited technologies and organisms can or will be safely and rigorously regulated by the proposed legislation, now and for future generations. Yet the proposed regulatory framework would radically place unknown quantities of genetically modified organisms (GMO) outside of any form of regulation.

If the Bill is passed, government officials and New Zealand exporters will be flying blind with a regulator that has no regulatory control because large numbers of gene edited technologies and organisms will escape any regulation.

With the Gene Technology Reform process, the failures in due diligence are numerable:

MBIE's [legislation promises to](#) 'enable the safe use of gene technologies and regulated organisms by managing their risks'. The new framework shifts (risk-tiers) many gene edited techniques and organisms (which are non-controversially accepted by scientists as [processes of genetic modification](#)) outside of any regulatory oversight. They would be considered as not-GMO for the purposes of regulation, and not declared, assessed or monitored.

94% of gene edited plants could be outside regulation. Unlike Europe, New Zealand would not just deregulate plants, but would deregulate microorganisms, fungi and animals as well. A European study [estimated](#) that 94% of GMO plants under the proposed 'non-GMO' class, which in Europe is more rigorous than New Zealand, could escape all regulation. No such evaluation has taken place in New Zealand.

No risk assessment. The [Good Regulatory Practice guidelines](#) require that systematic impact and risk analysis be undertaken. This did not occur, yet the legislation promises to *manage risks*. It is, of course, not possible to manage risks, if you do not even know what risks may arise from the GMOs that would be *inside* the legislative framework, but also those GMOs that would be risk-tiered *outside* of the legislation and regulatory oversight. Any DNA manipulations can involve risks. MBIE did not commission independent scientists to assess if the legislation was fit-for-purpose, even

though risk tiering of gene edited technologies and organisms *outside* of regulatory oversight is a novel regulatory approach. MBIE frankly do not know whether the bill could prevent harm and protect human or environmental health.

No cost-benefit analysis. The [Good Regulatory Practice guidelines](#) require cost benefit analysis to be undertaken and that any outcome should be achieved in the least-cost way. No cost benefit analysis was undertaken of the set-up costs of new legislation versus simply amending the existing HSNO Act. Instead, the Minister-in-charge directed officials not to include reform of the HSNO Act as a policy option during early stage consultation ([Regulatory Impact Statement](#) page 3).

No economic analysis. The [guidelines](#) require impact analysis on how the proposed change might align with international requirements. No systemic analysis of trade implications was undertaken. New Zealand will be vastly less regulated than the European Union, for example, should the Bill proceed.

No trade analysis. MBIE misled people by claiming that the legislation would bring New Zealand into line with our major trading partners, without undertaking a comprehensive analysis. However, the proposed changes would not align us with trading partners. The [Centre for Integrated Research in Biosafety \(INBI\) \(page 7\)](#) stated that *'in at least one significant way, New Zealand proposes to accept risks to human health and the environment unacceptable to any other country.'*

Removing the public right to know due to the risk-tiering outside the legislation. GMO-free food status is highly desired by premium markets, with a much [higher market growth rate](#) than conventional food. In our submission to the select committee, PSGR cited multiple studies ([page 14](#)) which show that consumers actively pay a premium for GMO-free food. The [Regulatory Impact Statement](#) acknowledges no research had been undertaken to estimate the value of this market.

Removing the Precautionary Approach. MBIE claims that precaution is outdated, and cites government papers to justify their claim. None of the cited papers stated that a precautionary approach was outdated. The claim [seems to have](#) come out of thin air.

The [August 2024 Regulatory Impact Analysis](#) (RIS) shows that MBIE did not undertake risk assessment, cost-benefit, economic analysis, or an analysis of the impact on New Zealand exporters. The RIS states plainly that there would be unquantified costs to non-GMO exporters, and that they were unable to quantify the expected benefits. The RIS acknowledges that MBIE did not engage broadly with Māori. (page 7)

MBIE-funded scientists are big proponents. The Productivity Commissioner had recommended wide-ranging consultation to review whether the legislation needed to be updated, with the general public and Māori. The Minister directed officials not to engage with the general public ([page 13](#)). MBIE carefully selected scientists and organisations to consult with, and excluded knowledgeable scientists who understood the nature of the risks of such DNA technologies. Most of the stakeholders chosen by MBIE had science funding from MBIE for gene editing research or were engaged in partnerships with MBIE-funded scientists. Most of these stakeholders had science funding from MBIE for gene editing research or were engaged in partnerships with MBIE-funded scientists.

Media has been biased towards deregulation. [Assoc Professor Valentina Dinica](#) reviewed media representations. Dinica confirmed that the vast majority of media articles were pro-genome editing, and did not undertake any critical analysis.

Consultation with Māori was not transparent. It mostly occurred under a MBIE-funded Plant and Food grant (no.C11X1602) that focussed on the benefits of new gene editing technologies and organisms and of the attitudes of Māori. Māori were not advised that no risk assessment had been undertaken. Māori were not advised that a considerable number of techniques and organisms would be exempt from any form of regulation.

No powers for the regulator to freely monitor and assess risks. The regulator lacks inquisitorial powers and cannot turn around and reassess the organisms outside the legislation.

Regulators are normally at arm's length from political agencies. This new legislation gives the power of administration of the law, and development of secondary legislation (where guidelines and rules would be contained), to MBIE. Unfortunately, MBIE, New Zealand's economic growth agency, controls the science budget and funds the scientists to develop GMOs. There is no independent funding set aside for scientists to study the risks from GMOs, including newer gene editing technologies. This is because MBIE's science policy is [focussed on](#) innovation and economic growth.

The policy and legislative deficits which underlie gene technology reform, deserve a far more critical eye than has so far occurred.

While much of the discussion by scientists about what gene editing technologies and organisms may do in future sounds exciting, much of it remains theoretical and speculative at best.

Laboratory development using biotechnology is not the concern of this communication to elected officials, rather it is the problem of uncontrolled and unmonitored releases of genetically modified organisms (GMOs) into New Zealand's environment.

The references below further outline the scientific issues, which include the non-controversial fact that all gene editors, including the technologies that would be risk tiered outside of regulation, are *powerful mutagens*. It's very evident that gene flow into the environment, and contamination (e.g. seed and pollen) from GM grasses under development is expected by the developers. The extent to which [off-target](#), and [non-target](#) effects could occur, should the Gene Technology Bill be enacted is simply unknown. At this stage the potential for such risks has not even been estimated, because MBIE failed to request a scientifically rigorous analysis for proof of concept.

(A PDF of the above letter is attached, and can also be [accessed online as a PDF](#)).

REFERENCES

- Centre for Integrated Research in Biosafety (INBI) (2025). [Submission to the Parliament Health Committee on the Gene Technology Bill 2024. Supplementary Submission.](#)
- PSGR (2025). [Submission to the Parliament Health Committee on the Gene Technology Bill.](#)
- PSGR (2025) [When powerful agencies hijack democratic systems. Part I: The case of gene technology regulatory reform.](#) Bruning, J.R., Dommissie, E.. ISBN 978-1-0670678-0-9

PSGR make a Local Government Official Information and Meetings Act 1987 request to Councillors (to be answered as one response from Councillors):

1. What concerns do Councillors hear from your constituents about gene editing technologies in food and the environment?
2. Have Councillors been made aware that there has been no risk assessment, economic assessment or cost-benefit assessment to assess the safety of the proposed Gene Technology Bill, including to structure some gene editing technologies and organisms completely outside of regulation?
3. Have Councillors been advised that the decision to remove the precautionary principle/approach was not made based on a review of best global practice?
4. Are Councillors aware that the gene edited technologies and organisms that following enactment of this Bill, that would be outside of regulation would never be monitored or declared?
5. How do you feel about the potential loss of local democratic control over GMO decisions in your region?
6. How might mayors collectively respond if the Gene Technology Bill overrides existing local precautionary and GMO policies without consultation (i.e. early-stage stakeholder consultation did not include elected members of TLAs)?

Thank you, we look forward to your response.

Kind regards| Ngā mihi



For the Trustees of
Physicians and Scientists for Global Responsibility

Social Media: @PSGRNZ

Twitter, Substack, Instagram, LinkedIn, Spotify, YouTube.

PSGR.org.nz



June 16, 2025.

Letter to Councillors of regional councils and territorial authorities (TLAs). Re: Gene Technology Bill.

Dear Councillor,

By now, elected members and staff at TLAs will be reading articles in local agricultural papers and in the accredited media, discussing the benefits to New Zealand of the [Gene Technology Bill](#), currently at the select committee stage. Public submissions closed in February, yet the report to the Select Committee remains unpublished.

We urge elected members to be circumspect. Few articles have frankly addressed the deficiencies in the policy formulation. This was highlighted by both scientists and legal experts in their Select Committee submissions. As elected members you recognise the importance of step-by-step processes that follow transparent and accountable stages, as per the Good Regulatory Practice guidelines. End-stage policy and law must be of high quality.

The Ministry for Business, Innovation and Employment and the Minister in charge, the Hon Judith Collins, advised all that they were pushing the policy and Bill through at a fast pace. Unfortunately, it shows. Neither a scientific case nor an economic case was made for the reforms. The evidence base in the Regulatory Impact Statement does not demonstrate that gene edited technologies and organisms can or will be safely and rigorously regulated by the proposed legislation, now and for future generations. Yet the proposed regulatory framework would radically place unknown quantities of genetically modified organisms (GMO) outside of any form of regulation.

If the Bill is passed, government officials and New Zealand exporters will be flying blind with a regulator that has no regulatory control because large numbers of gene edited technologies and organisms will escape any regulation.

With the Gene Technology Reform process, the failures in due diligence are numerable:

MBIE's [legislation promises to](#) 'enable the safe use of gene technologies and regulated organisms by managing their risks'. The new framework shifts (risk-tiers) many gene edited techniques and organisms (which are non-controversially accepted by scientists as [processes of genetic modification](#)) outside of any regulatory oversight. They would be considered as not-GMO for the purposes of regulation, and not declared, assessed or monitored.

94% of gene edited plants could be outside regulation. Unlike Europe, New Zealand would not just deregulate plants, but would deregulate microorganisms, fungi and animals as well. A European study [estimated](#) that 94% of GMO plants under the proposed 'non-GMO' class, which in Europe is more rigorous than New Zealand, could escape all regulation. No such evaluation has taken place in New Zealand.

No risk assessment. The [Good Regulatory Practice guidelines](#) require that systematic impact and risk analysis be undertaken. This did not occur, yet the legislation promises to *manage risks*. It is, of course, not possible to manage risks, if you do not even know what risks may arise from the GMOs that would be *inside* the legislative framework, but also those GMOs that would be risk-tiered *outside* of the legislation and regulatory oversight. Any DNA manipulations can involve risks. MBIE did not commission independent scientists to assess if the legislation was fit-for-purpose, even though risk tiering of gene edited technologies and organisms *outside* of regulatory oversight is a novel regulatory approach. MBIE frankly do not know whether the bill could prevent harm and protect human or environmental health.

No cost-benefit analysis. The [Good Regulatory Practice guidelines](#) require cost benefit analysis to be undertaken and that any outcome should be achieved in the least-cost way. No cost benefit analysis was undertaken of the set-up costs of new legislation versus simply amending the existing HSNO Act. Instead, the Minister-in-charge directed officials not to include reform of the HSNO Act as a policy option during early stage consultation ([Regulatory Impact Statement](#) page 3).

No economic analysis. The [guidelines](#) require impact analysis on how the proposed change might align with international requirements. No systemic analysis of trade implications was undertaken. New Zealand will be vastly less regulated than the European Union, for example, should the Bill proceed.

No trade analysis. MBIE misled people by claiming that the legislation would bring New Zealand into line with our major trading partners, without undertaking a comprehensive analysis. However, the proposed changes would not align us with trading partners. The [Centre for Integrated Research in Biosafety \(INBI\) \(page 7\)](#) stated that 'in at least one significant way, New Zealand proposes to accept risks to human health and the environment unacceptable to any other country.'

Removing the public right to know due to the risk-tiering outside the legislation. GMO-free food status is highly desired by premium markets, with a much [higher market growth rate](#) than conventional food. In our submission to the select committee, PSGR cited multiple studies ([page 14](#)) which show that consumers actively pay a premium for GMO-free food. The [Regulatory Impact Statement](#) acknowledges no research had been undertaken to estimate the value of this market.

Removing the Precautionary Approach. MBIE claims that precaution is outdated, and cites government papers to justify their claim. None of the cited papers stated that a precautionary approach was outdated. The claim [seems to have](#) come out of thin air.

The [August 2024 Regulatory Impact Analysis](#) (RIS) shows that MBIE did not undertake risk assessment, cost-benefit, economic analysis, or an analysis of the impact on New Zealand exporters. The RIS states plainly that there would be unquantified costs to non-GMO exporters, and that they were unable to quantify the expected benefits. The RIS acknowledges that MBIE did not engage broadly with Māori. (page 7)

MBIE-funded scientists are big proponents. The Productivity Commissioner had recommended wide-ranging consultation to review whether the legislation needed to be updated, with the general public and Māori. The Minister directed officials not to engage with the general public ([page 13](#)). MBIE carefully selected scientists and organisations to consult with, and excluded knowledgeable scientists who understood the nature of the risks of such DNA technologies. Most of the stakeholders chosen by MBIE had science funding from MBIE for gene editing research or were engaged in partnerships with MBIE-funded scientists. Most of these stakeholders had science funding from MBIE for gene editing research or were engaged in partnerships with MBIE-funded scientists.

Media has been biased towards deregulation. [Assoc Professor Valentina Dinica](#) reviewed media representations. Dinica confirmed that the vast majority of media articles were pro-genome editing, and did not undertake any critical analysis.

Consultation with Māori was not transparent. It mostly occurred under a MBIE-funded Plant and Food grant (no.C11X1602) that focussed on the benefits of new gene editing technologies and organisms and of the attitudes of Māori. Māori were not advised that no risk assessment had been undertaken. Māori were not advised that a considerable number of techniques and organisms would be exempt from any form of regulation.

No powers for the regulator to freely monitor and assess risks. The regulator lacks inquisitorial powers and cannot turn around and reassess the organisms outside the legislation.

Regulators are normally at arm's length from political agencies. This new legislation gives the power of administration of the law, and development of secondary legislation (where guidelines and rules would be contained), to MBIE. Unfortunately, MBIE, New Zealand's economic growth agency, controls the science budget and funds the scientists to develop GMOs. There is no independent funding set aside for scientists to study the risks from GMOs, including newer gene editing technologies. This is because MBIE's science policy is [focussed on](#) innovation and economic growth.

The policy and legislative deficits which underlie gene technology reform, deserve a far more critical eye than has so far occurred.

While much of the discussion by scientists about what gene editing technologies and organisms may do in future sounds exciting, much of it remains theoretical and speculative at best.

Laboratory development using biotechnology is not the concern of this communication to elected officials, rather it is the problem of uncontrolled and unmonitored releases of genetically modified organisms (GMOs) into New Zealand's environment.

The references below further outline further the scientific issues, which include the non-controversial fact that all gene editors, including the technologies that would be risk tiered outside of regulation, are *powerful mutagens*. It's very evident that gene flow into the environment, and contamination (e.g. seed and pollen) from GM grasses under development is expected by the developers. The extent to which [off-target](#), and [non-target](#) effects could occur, should the Gene Technology Bill be enacted is simply unknown. At this stage the potential for such risks has not even been estimated, because MBIE failed to request a scientifically rigorous analysis for proof of concept.

REFERENCES

- Centre for Integrated Research in Biosafety (INBI) (2025). [Submission to the Parliament Health Committee on the Gene Technology Bill 2024. Supplementary Submission.](#)
- PSGR (2025). [Submission to the Parliament Health Committee on the Gene Technology Bill.](#)
- PSGR (2025) [When powerful agencies hijack democratic systems. Part I: The case of gene technology regulatory reform.](#) Bruning, J.R., Dommissie, E.. ISBN 978-1-0670678-0-9